PHIO - Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO) | Benzinga
MARLBOROUGH, Mass., April 30, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced it is presenting new data about its lead product candidate, PH-762, an INTASYL compound.
PH-762 is currently being studied in a US clinical trial to assess safety and efficacy in specific skin cancers. (NCT 06014086). This open-label Phase 1b clinical study (NCT 06014086) is designed to evaluate the safety and tolerability of neoadjuvant use of IT PH-762 in Stages 1,2 and 4 cutaneous squamous cell carcinoma, Stage 4 melanoma and Stage 4 Merkel cell carcinoma. Stages 1 and 2 cSCC represent 77% of all new cSCC annually. There are no drug products approved for treatment of Stages 1 and 2 cSCC.
The data will be presented at the annual meeting of the American Society of Clinical Oncology (ASCO) to be held in Chicago, Illinois.
Title: INTASYL™ PH-762: PD-1 Intratumoral Immunotherapy for Cutaneous Carcinoma
| Poster Number: |
| TPS9620 |
| Topic: |
| Melanoma/Skin Cancer |
| Presenting Author: |
| Mary Spellman, M.D. |
| Date and Time: |
| June 1, 2024: 1:30-4:30 ... |